Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
$12.50
+0.1%
$12.50
$7.22
$12.51
$799.18M1.391.45 million shs3.07 million shs
Chimerix, Inc. stock logo
CMRX
Chimerix
$8.54
$8.54
$0.75
$8.55
$801.09M-0.172.80 million shsN/A
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
$3.46
+4.2%
$2.54
$1.61
$11.20
$212.57M0.86838,394 shs719,781 shs
Oculis Holding AG stock logo
OCS
Oculis
$18.43
-1.1%
$18.95
$10.79
$23.08
$813.87M0.2945,351 shs10,438 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
0.00%0.00%0.00%0.00%+64.84%
Chimerix, Inc. stock logo
CMRX
Chimerix
0.00%0.00%0.00%+0.12%+940.96%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
+4.22%+11.25%+30.08%+94.38%-60.93%
Oculis Holding AG stock logo
OCS
Oculis
-1.13%-3.81%-7.48%+14.12%+67.39%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
0.8884 of 5 stars
1.00.00.04.50.01.70.6
Chimerix, Inc. stock logo
CMRX
Chimerix
0.6104 of 5 stars
1.00.00.04.10.01.70.6
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
1.4923 of 5 stars
3.61.00.00.01.11.70.0
Oculis Holding AG stock logo
OCS
Oculis
1.727 of 5 stars
3.53.00.00.00.60.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
2.00
Hold$12.25-1.96% Downside
Chimerix, Inc. stock logo
CMRX
Chimerix
2.00
Hold$8.53-0.08% Downside
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3.11
Buy$18.50434.68% Upside
Oculis Holding AG stock logo
OCS
Oculis
3.00
Buy$35.3391.72% Upside

Current Analyst Ratings Breakdown

Latest LRMR, OCS, CMRX, and CDMO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
6/24/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$17.00 ➝ $15.00
6/24/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$26.00
5/9/2025
Oculis Holding AG stock logo
OCS
Oculis
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$28.00 ➝ $33.00
4/17/2025
Oculis Holding AG stock logo
OCS
Oculis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$29.00 ➝ $32.00
4/17/2025
Oculis Holding AG stock logo
OCS
Oculis
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
$139.91M5.71$0.15 per share80.92$3.02 per share4.14
Chimerix, Inc. stock logo
CMRX
Chimerix
$212K3,778.71N/AN/A$2.17 per share3.94
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/A$2.69 per shareN/A
Oculis Holding AG stock logo
OCS
Oculis
$780K1,031.61N/AN/A$1.91 per share9.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
-$140.75M-$2.39N/AN/AN/A-101.07%-33.18%-8.45%9/8/2025 (Estimated)
Chimerix, Inc. stock logo
CMRX
Chimerix
-$82.10M-$0.99N/AN/AN/AN/A-50.78%-44.94%8/11/2025 (Estimated)
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$80.60M-$1.49N/AN/AN/AN/A-52.48%-46.08%8/6/2025 (Estimated)
Oculis Holding AG stock logo
OCS
Oculis
-$97.43M-$2.64N/AN/AN/A-13,788.70%-92.95%-70.03%8/26/2025 (Estimated)

Latest LRMR, OCS, CMRX, and CDMO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$0.4877N/AN/AN/AN/AN/A
5/8/2025Q1 2025
Oculis Holding AG stock logo
OCS
Oculis
-$0.51-$0.77-$0.26-$0.77$0.22 million$0.32 million
4/30/2025Q1 2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$0.42-$0.46-$0.04-$0.46N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
N/AN/AN/AN/AN/A
Chimerix, Inc. stock logo
CMRX
Chimerix
N/AN/AN/AN/AN/A
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/AN/A
Oculis Holding AG stock logo
OCS
Oculis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
3.58
1.30
0.92
Chimerix, Inc. stock logo
CMRX
Chimerix
N/A
6.33
6.33
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/A
7.48
7.48
Oculis Holding AG stock logo
OCS
Oculis
N/A
4.79
4.79

Institutional Ownership

CompanyInstitutional Ownership
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
97.16%
Chimerix, Inc. stock logo
CMRX
Chimerix
45.42%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
91.92%
Oculis Holding AG stock logo
OCS
Oculis
22.30%

Insider Ownership

CompanyInsider Ownership
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
3.05%
Chimerix, Inc. stock logo
CMRX
Chimerix
13.10%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
4.50%
Oculis Holding AG stock logo
OCS
Oculis
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
32063.96 million62.01 millionOptionable
Chimerix, Inc. stock logo
CMRX
Chimerix
9093.80 million78.15 millionOptionable
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3064.03 million61.15 millionOptionable
Oculis Holding AG stock logo
OCS
Oculis
243.66 millionN/ANot Optionable

Recent News About These Companies

OCS - Oculis Holding AG Executives - Morningstar
Oculis Holding AG (OCS) - Yahoo Finance
Oculis to Participate in Upcoming June Investor Conferences
Oculis posts widening quarterly loss as R&D spend climbs

New MarketBeat Followers Over Time

Media Sentiment Over Time

Avid Bioservices stock logo

Avid Bioservices NASDAQ:CDMO

$12.50 +0.02 (+0.12%)
Closing price 02/5/2025
Extended Trading
$12.50 0.00 (0.00%)
As of 02/5/2025 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.

Chimerix stock logo

Chimerix NASDAQ:CMRX

$8.54 0.00 (0.00%)
As of 04/21/2025

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Larimar Therapeutics stock logo

Larimar Therapeutics NASDAQ:LRMR

$3.46 +0.14 (+4.22%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$3.45 -0.01 (-0.32%)
As of 04:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Oculis stock logo

Oculis NASDAQ:OCS

$18.43 -0.21 (-1.13%)
As of 07/9/2025 04:00 PM Eastern

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.